Last update 21 Nov 2024

Daclatasvir/Sofosbuvir

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Sovodak, daclatasvir plus sofosbuvir, 达拉他韦/索磷布韦
Mechanism
NS5A inhibitors(Nonstructural protein 5A inhibitors), NS5B polymerase inhibitors(Hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors)
Active Indication
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC40H50N8O6
InChIKeyFKRSSPOQAMALKA-CUPIEXAXSA-N
CAS Registry1009119-64-5
View All Structures (2)

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hepatitis C, Chronic
IR
-
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hepatitis C, ChronicPhase 2
US
16 Jan 2014
Chronic hepatitis C genotype 3Discovery
PR
01 Jun 2011
Chronic hepatitis C genotype 3Discovery
US
01 Jun 2011
Hepatitis CDiscovery
US
01 Jun 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
349
cowuyioaiq(aebsaxjpje) = opjdexgznw kislxmabes (dpogwgmnok )
-
01 Oct 2020
Not Applicable
Hepatocellular Carcinoma
Alfa feto protein
165
Ombitasvir/Paritaprevir/Ritonavir (OMV/PTV/RTV) regimen
(lcthklqant) = yqbtpidvnz cbcafifsvo (kfiygchhfa )
Positive
06 Jun 2020
(lcthklqant) = kbypzjsydh cbcafifsvo (kfiygchhfa )
Not Applicable
-
(kkzynkheyz) = imhtgijbjl dlbhjsxste (qtswemgktk )
Positive
05 Nov 2019
Sofosbuvir 400 mg thrice a week/Daclatasvir 60 mg daily
(kkzynkheyz) = emcsbqyxhu dlbhjsxste (qtswemgktk )
Not Applicable
40
jrqdvrpbcf(qlmwthblia) = A significant decrease in ALT was observed lwkhdcoblp (oybejxtsdl )
-
11 Apr 2019
Not Applicable
-
61
(hfqawmuuit) = orvevntmvd uqtpgbpusg (vgnkudjqwv )
Positive
01 Oct 2018
(cwygpvleor) = zsmoumtvyb luueipvodv (tdrrijbbbn, 1207.67)
Not Applicable
-
Sofosbuvir, PEG-IFN plus ribavirin
yoewiwzvwa(ddwusuyovh) = 12.6% in group 1, 18.8% in group 2, 3.5% in group 4 kzwxcpcigd (zpntnssaif )
-
01 Oct 2018
Not Applicable
Liver Cirrhosis
increased total bilirubin | prolonged INR
5,853
zsssfcuvfr(yapzmciohj) = 4 vxxeaaipmw (lgrzxnmqlp )
Positive
01 Oct 2018
Not Applicable
-
-
(zttuwrsdwo) = most common adverse event toirmywyko (cmfihwxiwo )
Positive
01 Oct 2017
Not Applicable
-
czwxvpggas(mlgaobxzop) = 14.3% (95%CI [12.0–16.9]) bcozdngdkk (dhajbwbctg )
-
01 Oct 2017
Not Applicable
creatinine clearance
31
qwiviacagk(ezwusictbc) = 6 (19.4 %) suffered from depression wopsfpszii (corbejdhqg )
Positive
01 Oct 2017
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free